drugset
drugset / Trial / NCT05170204

A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)

NCT05170204 ↗

Phase 3 Active not recruiting 68 enrolled Hoffmann-La Roche
RandomizedParallel-groupOpen-labelTreatment

Summary

This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control (AJCC/UICC) NSCLC staging system.

Timeline

Start
2022-11-01
Primary completion
2030-06-16
Completion
2030-06-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Alectinib Small molecule 600 mg Oral
Comparator Durvalumab Monoclonal antibody 1500 mg Intravenous
Subject Entrectinib Small molecule 600 mg Oral

Indications

non-small cell lung carcinoma